Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Huayi’s Diabetes Drug Enters Phase III

This article was originally published in PharmAsia News

Executive Summary

Shanghai Huayi (Group) has started its Phase III trial for rhGLP-1, the first China-made incretin mimetic drug for treating type 2 diabetes. The clinical trial will be conducted in 14 major cities nationwide, covering nearly 20 hospitals with rich experience in endocrinology. With treatment effectiveness superior to traditional diabetes drugs, rhGLP-1 has received more than 10 domestic and overseas patents. To support registration and production of its new drugs, Huayi is stepping up the establishment of its pilot and industrial base such that phase one of the project will be completed next May. The firm expects rhGLP-1 to be launched within two years at a price far lower than similar imported products. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067493

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel